Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of 611 in moderate-to-severe COPD in China
CTR20252166Phase 3Active
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of SSGJ-611 in chronic obstructive pulmonary disease (COPD), sponsored by 3S Guojian Pharmaceutical. Started Jul 2025; status: active.
02
Drugs
SSGJ-611
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20252166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252166.